Williams Timothy purchased $11K of GERN
Williams Timothy (EVP and Chief Legal Officer) purchased 12,000 shares of GERON CORP (GERN) at $0.94 on 2026-11-16.
GERON CORP
Geron is a commercial-stage biopharmaceutical company that develops and commercializes treatments for blood cancers. Its main product is RYTELO (imetelstat), a telomerase inhibitor approved in the United States and European Union for certain adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes. Geron launched RYTELO in the United States in June 2024 and plans to work with third parties on commercialization in select EU markets. It also makes RYTELO available outside the United States through Named Patient Programs with distributor Tanner Pharma. Geron is studying imetelstat in clinical trials for myelofibrosis and other blood cancers, and has a discovery program for potential next-generation oral telomerase inhibitors. The company holds global commercial rights to RYTELO. It is headquartered in Foster City, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $GERN in the last 7 days.
Williams Timothy (EVP and Chief Legal Officer) purchased 12,000 shares of GERON CORP (GERN) at $0.94 on 2026-11-16.
Semerjian Harout (President & CEO) purchased 53,500 shares of GERON CORP (GERN) at $0.95 on 2026-11-13.
Geron (GERN) plans to launch RYTELO in Germany, aiming to set a price before the country's pricing process. The company expects higher SGA expenses next year but has reduced operating costs by $10M this year. After discontinuing a Phase 3 trial, Geron focuses on growing its business, expanding RYTELO internationally, and pursuing deals. The company reported profitability in the latest quarter and believes it has sufficient cash for future operations.
Recent GERN coverage spans financial news, insider activity and earnings.
In the last 30 days, GERN insiders filed 2 SEC Form 4 transactions — 2 purchases ($62K) and no sales. The most active reporter was Semerjian Harout, President & CEO, with 1 filing.
Insider open-market purchase is modest-sized and typically signals alignment, but it is unlikely to drive a large repricing by itself.
Likely mild positive sentiment from insider buying, but the dollar size is small and unlikely to drive price by itself.
The German launch could open a new revenue stream and set a pricing benchmark for other markets, while SG&A expenses may rise.
Earnings beat and profit swing likely drive short-term upside.
Geron issued guidance with lowered operating expenses and reaffirmed revenue range.
AlphAI scores every news story that mentions GERN with an AI model for sentiment and relevance, and aggregates insider trades from GERON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Williams Timothy (EVP and Chief Legal Officer) purchased 12,000 shares of GERON CORP (GERN) at $0.94 on 2026-11-16.
Semerjian Harout (President & CEO) purchased 53,500 shares of GERON CORP (GERN) at $0.95 on 2026-11-13.
Geron (GERN) plans to launch RYTELO in Germany, aiming to set a price before the country's pricing process. The company expects higher SGA expenses next year but has reduced operating costs by $10M this year. After discontinuing a Phase 3 trial, Geron focuses on growing its business, expanding RYTELO internationally, and pursuing deals. The company reported profitability in the latest quarter and believes it has sufficient cash for future operations.
Geron reported Q3 2026 revenue of $60.1M, up from $47.2M a year earlier, with net income of $1.4M. Operating income was $5.8M, reversing a prior-year loss. The company maintained its 2026 RYTELO revenue outlook but lowered operating expense guidance. RYTELO demand increased 10% from Q2 2026, and Geron initiated a commercial launch in Europe.
GERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-t
GERON CORP (GERN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis FOSTER CITY, Calif., – October 28, 2026 – Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announce
Needham kept its Buy rating on Geron with a $2.50 price target, suggesting 117.4% upside from the Oct 27 close. Analysts highlight RYTELO's potential in treating LR-MDS and Geron's focus on its core development, which supports the positive outlook.
Wedbush reduced its price target for Geron (GERN) to $5 from $6, citing the discontinuation of the IMpactMF study, but maintained an Outperform rating. The firm noted no new safety signals and expects Rytelo's commercial trajectory to remain intact. Geron reported $57.5M in Q2 2026 revenue, up 11% sequentially, and 24% year-over-year growth over the last twelve months. The stock trades near its 52-week low of $1.04.
Geron Corporation (GERN) will discontinue its Phase 3 IMpactMF trial for imetelstat in myelofibrosis after the Data Monitoring Committee advised it was unlikely to meet the primary survival endpoint. The company will analyze the data and share findings later. Geron remains focused on its commercial business and growing demand for RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS).
Geron Corporation (GERN) presented data on imetelstat, its treatment for lower-risk myelodysplastic syndromes (LR-MDS), at two hematology conferences. A U.S. study showed 67% of 58 patients remained on treatment at six months. The company highlighted real-world evidence and clinical trial results, emphasizing global interest in imetelstat. Geron aims to expand its use in LR-MDS and other hematologic malignancies.